C2N Diagnostics Receives $15 Million Program Related Investment from GHR Foundation to Develop Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease
September 30, 2024 09:57 AM Eastern Daylight Time ST. LOUIS–(BUSINESS WIRE)–C2N Diagnostics, LLC (C2N), a world leader in developing Alzheimer’s disease-specific fluid biomarker tests, has received a new $15 million program-related investment from GHR Foundation (GHR) to…
